MedTrace Logo

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors

NCT02303444 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 667

Last updated 2023-06-08

No results posted yet for this study

Summary

The purpose of the study was to assess the use of Multikinase Inhibitors (MKIs) in the treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) who do not have any symptoms.

Conditions

  • Thyroid Neoplasms

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Patients can get sorafenib at any time during study.

DRUG

Other Multikinase inhibitors

Patients can get MKIs at any time during study.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-08
Primary Completion
2020-06-10
Completion
2020-07-24

Countries

  • United States
  • Algeria
  • Argentina
  • Brazil
  • Egypt
  • France
  • Germany
  • Greece
  • India
  • Japan
  • Lebanon
  • Mexico
  • Netherlands
  • Philippines
  • Russia
  • Saudi Arabia
  • Spain
  • Taiwan
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02303444 on ClinicalTrials.gov